Summary
Gilead Sciences, Inc. (GILD) disclosed in this Form 8-K filing that its San Dimas, California manufacturing facility received a Warning Letter from the U.S. Food and Drug Administration (FDA) on September 24, 2010. This letter stems from a January-February 2010 inspection that identified inadequacies in areas such as control systems, prevention of microbiological contamination, and quality control procedures, particularly concerning the manufacturing of AmBisome and certain lots of Viread. Gilead stated it believes it has addressed the FDA's observations and is working to resolve outstanding concerns.
Key Highlights
- 1Gilead's San Dimas, CA manufacturing facility received an FDA Warning Letter on September 24, 2010.
- 2The Warning Letter follows an FDA cGMP inspection conducted in January and February 2010.
- 3Identified inadequacies include issues with control systems, microbiological contamination prevention, cleaning, maintenance, and quality procedures related to AmBisome and Viread.
- 4Gilead believes it has addressed the FDA's observations and is working to resolve any remaining concerns.
- 5The FDA may withhold permission to export AmBisome to certain countries outside the US and Europe.
- 6The FDA may also withhold approval of pending drug applications listing the San Dimas facility.
- 7Gilead has notified international regulatory authorities, and the letter could impact the supply of aseptic products (AmBisome, Cayston, Macugen) manufactured at San Dimas globally, but not solid dosage form products.
Frequently Asked Questions
The main issue is that Gilead Sciences received a Warning Letter from the FDA regarding its San Dimas, California manufacturing facility due to cGMP violations identified during an inspection.
The Warning Letter specifically mentions concerns related to the manufacturing of AmBisome and certain lots of Viread. Gilead states that the letter may impact the ability to supply aseptic products manufactured at San Dimas, including AmBisome, Cayston, and Macugen, outside the US and Europe. Solid dosage form products are not expected to be affected.
Gilead states that it believes it has addressed the FDA's observations from the inspection and is diligently working to resolve any outstanding concerns listed in the Warning Letter to the FDA's satisfaction.
Potential consequences include the FDA withholding permission to export AmBisome to certain international markets and withholding approval of pending drug applications that list the San Dimas facility. It may also impact the global supply of other aseptic products manufactured at the facility. Gilead also notes that international regulatory authorities have been notified and could take similar actions.